Biocept is offering 1,176,470 shares of its common stock and warrants for up to 2,352,940 shares of BIOC stock. These units are priced at $4.25 per share and include one share and one warrant to purchase another share. The warrants also have an exercise price of $4.25.
According to Biocept, the public offering will see it raise $5 million. The company says it will use this cash to advance its FORESEE trial for CNSide, working capital, as well as general corporate purposes.
To go along with this, Biocept has granted underwriters the option to acquire an additional 176,470 shares of BIOC stock and warrants for another 352,940 shares. This offer lasts for 45 days and is priced the same as the public offering.
BIOC Stock Movement Today
Investors aren’t reacting well to today’s public offering news with BIOC shares falling. That makes sense as it increases the total number of outstanding shares of BIOC stock. That dilutes the stakes that current investors have in the company.
Today’s news also brings with it heavy trading of BIOC stock. As of this writing, more than 364,000 shares of the stock have changed hands. That’s already above its daily average trading volume of about 113,000 shares.
BIOC stock is down 42.1% as of Thursday morning.
Investors can find more of the most recent stock market news ready to go below!
We’ve got all of the hottest stock market news for traders to read about on Thursday! A few examples include why shares of Wireless Telecom Group (NYSEMKT:WTT) and Kubient (NASDAQ:KBNT) stock are climbing today, as well as the biggest pre-market stock movers today. All of that news is available at the following links!
More Thursday Stock Market News
On Penny Stocks and Low-Volume Stocks:?With only the rarest exceptions, InvestorPlace does not publish commentary about companies that have a market cap of less than $100 million or trade less than 100,000 shares each day. That’s because these “penny stocks” are frequently the playground for scam artists and market manipulators. If we ever do publish commentary on a low-volume stock that may be affected by our commentary, we demand that?InvestorPlace.com’s writers disclose this fact and warn readers of the risk.
On the date of publication, William White did not have (either directly or indirectly) any positions in the securities mentioned in this article. The opinions expressed in this article are those of the writer, subject to the InvestorPlace.com Publishing Guidelines.